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Abstract. Loss of heterozygosis (LOH) on chromosome 
(Chr) 18q21-23 was reported to be one of the most common 
genetic alterations identified in bladder cancer. The current 
study aimed to determine the prognostic role of LOH on 
Chr 18q21-23 in patients diagnosed with muscle-invasive 
urothelial bladder carcinoma (MIBC). A total of 34 consecu-
tive patients were enrolled in the present prospective study. 
LOH on Chr 18 was assessed by performing multiplex 
polymerase chain reaction on paired blood and tumour tissue 
samples from each patient. The following primers were used 
in the present study: D18S51, MBP LW and MBP H. These 
data were then compared with follow-up information. The 
main outcome measure was patient status at the end of the 
follow-up. Cox regression was used to evaluate the impact of 
each parameter on cancer-specific survival and the Kaplan 
Meier test for disease-free survival was plotted in order to 
estimate survival. Out of 34 patients, 18 (52.9%) exhibited 
≥1 alteration in one of the loci analysed on chromosome 18, 
while 16 (47.1%) revealed no alterations. No correlation was 
identified with stage (P=0.18) or grade (P=0.06); however, 
LOH on Chr 18q21-23 was significantly associated with a 
lower recurrence-free probability (P<0.0001). Kaplan-Meier 
curves demonstrated a significant association between patient 
status at follow-up and LOH on Chr 18 (P<0.001). In addition, 
multivariate analysis identified LOH on Chr 18 (P<0.001) and 
stage (P=0.01) as independent survival predictors. Further-
more, artificial neural network analysis was consistent with 
the results of the multivariate analysis. In conclusion, the 
present study highlighted the role of LOH on Chr 18q21-23 in 
predicting the clinical outcome of patients with MIBC.
Introduction
Urothelial carcinoma (UC) of the urinary bladder is a 
relevant social problem with almost 67,160 novel cases 
diagnosed each year and accounts for ~13,750 cancer-asso-
ciated mortalities each year in the United States (1). 
Mhawech-Fauceglia et al (2) suggested that the pathology of 
bladder carcinoma was a difficult to fully elucidate due to the 
complex oncogenic pathways involved and the inconsistent 
clinical behaviour of the disease. 
Numerous previous studies have identified potential 
molecular markers for bladder carcinoma in an effort to 
fully elucidate the cellular mechanisms involved in its patho-
genesis and development. Consequently, the prediction of 
tumour biological potential may help to select patients for 
treatment, thus improving the survival rates and quality of 
life of these patients (3-5). Tumour genome analysis has been 
used to obtain information regarding the natural history of 
UC (6). Of note, the loss of heterozygosis (LOH) on chromo-
some (Chr) 18 was reported to be the initial genetic event in 
bladder cancer (7).
As tumour-suppressor genes, including the DCC (18q21.3) 
and DPC4 (18q21.1) genes were identified on Chr 18q (8), 
it was suggested that somatic alterations on this chromo-
some may be a critical step for bladder carcinogenesis. In 
addition, it was reported that loss or inactivation of the 
SMAD4/DPC4 gene may be involved in the onset of various 
types of cancer, while LOH of 18q21.1 was demonstrated to 
be associated with a poor prognosis in bladder carcinoma 
patients (8). The distal section of Chr 18 (18q21-q23) was 
considered to be a potential locus of numerous crucial genes 
for the pathogenesis and progression of bladder cancer. A 
previous study highlighted the role of LOH analysis of Chr 18 
for enhancing the prediction of recurrence in patients with 
low-grade non-muscle-invasive bladder cancer (4); however, 
further studies are required. Notably, the D18S51, MBP LW 
and MBP H loci are located on the long arm of Chr 18, where 
a number of tumor suppressor genes, including DCC and 
DPC4, are located (6).
The present study aimed to evaluate LOH on Chr 18 in 
patients with muscle-invasive urothelial bladder cell carci-
nomas in order to determine whether there is an association 
between LOH on Chr 18 and tumour stage. In addition, the 
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present study aimed to investigate whether LOH on Chr 18 
has a role in predicting the clinical outcome of patients with 
muscle-invasive urothelial bladder cancer.
Materials and methods
Study design. LOH on Chr 18 was investigated in muscle-inva-
sive UC of the urinary bladder and the findings were then 
correlated with patient follow-up data. A total of 34 consecu-
tive patients were recruited for the present prospective study 
who underwent a transurethral resection of bladder tumour 
(TURBT) at the Department of Urology, University of Flor-
ence (Florence, Italy), between January and December 2002. 
All patients enrolled in the present study were diagnosed with 
muscle-invasive urothelial bladder cancer [MIBC; ≥primary 
tumour stage (pT)2, according to the European Association of 
Urology guidelines] and were able to comply with the follow-up 
schedules. Patients were excluded if they had a history of UC 
of the upper urinary tract, prostate cancer or other urologic 
cancer; in addition, patients with associated carcinoma in situ 
were omitted from the present study. All patients with other 
urologic diseases were also excluded, as were all patients lost 
to follow-up. All selected patients provided written informed 
consent and the study was approved by the research ethics 
committee of the University of Florence. The present study 
was conducted in accordance with the latest version of the 
Declaration of Helsinki (2008) and in line with Good Clinical 
Practice guidelines (9).
Specimen collection, histological and molecular analysis. 
Blood samples were collected from all patients during clinical 
evaluation and stored at -80˚C until molecular analysis. Fresh 
tumour tissue samples were obtained during TURBT for path-
ological evaluation and were snap-frozen in liquid nitrogen 
in the operating room and stored at -80˚C until molecular 
analysis. Tumour and normal DNA were extracted using the 
methods previously described (5). Briefly, the DNA of each 
sample underwent digestion with sodium dodecyl sulfate 
proteinase K (recombinant; Worthington Biochemical Corpo-
ration, Lakewood, NJ, USA; 55˚C overnight), ribonuclease 
(Multiplex PCR Kit; Qiagen Spa, Milan, Italy) treatment (2 h 
at 37˚C) and phenol chloroform (Life Technologies Italia, 
Monza, Italy)  extraction. DNA was resuspended in 700 ml 
Tris EDTA (Life Technologies Italia). The quantity of DNA 
was evaluated by spectrophotometry optical density (Nano-
Drop® 1000UV spectrophotometer; Thermo Fisher Scientific, 
Inc., Wilmington, DE, USA), and the samples were diluted 
to a concentration of 4 ng/µl for amplification by polymerase 
chain reaction (PCR). PCR was performed in a final volume 
of 15 ml with 10 ng DNA in order to amplify genomic DNA at 
three specific Chr 18 loci: D18S51, MBP LW and MBP H. The 
primer sequences were as follows: Forward, 5'-TTC TTG AGC 
CCA GAA GGT TA-3' and reverse, 5'-ATT CTA CCA GCA ACA 
ACA CAA ATA AAC-3' for D18S51; forward, 5'-TGG CTA 
CTT GGG CTA TTG TAA ACG-3' and reverse, 5'-GGT GGT 
TCT GTT CCC TCT ATC TCC-3' for MBP LW; and forward, 
5'-TCC GAG CAG CAG CCA GCA C-3' and reverse, 5'-AAG 
CTC GTC GGA CTC TGA G-3' for MBP H. Each primer was 
fluorescently marked with the dyes 6-FAM, NED and HEX 
(Applied Biosystems Life Technologies, Foster City, CA, 
USA). Normal and pathological DNA underwent amplifica-
tion in an Applied Biosystems® 2720 Thermal Cycler (Life 
Technologies Italia); three PCRs were performed per patient. 
The amplification conditions of the reactions were a denatur-
ation cycle at 95˚C for 10 min, 32 cycles at 95˚C for 30 sec, 56˚C 
for D18S51 and 52˚C for MBP LW and MBP H, for 30 sec, and 
72˚C for 1 min, and final extension at 72˚C for 45 min. DNA 
quality was assessed by agarose gel and ethidium bromide 
staining (Life Technologies Italia). Amplification products (1 µl) 
were mixed with 12 µl formamide (molecular biology grade; 
Life Technologies Italia) and 0.5µl GeneScan ROX400 (Perkin 
Elmer Biosystems, Foster City, CA, USA), denatured at 95˚C 
for 10 min and then rapidly iced. Up to 48 samples were then 
electrophoresed in an ABI Prism® 310 Genetic Analyzer (Life 
Technologies Italia). Amplification products (50 µl) were injected 
electrokinetically in a 47 cm capillary (Applied Biosystems 
Life Technologies) filled by performance optimized polymer 4 
(Life Technologies Italia). Electrophoresis was conducted at 
15 kV for 24 min at 60˚C and electrodes were immersed in ABI 
Prism® 310 Genetic Analyzer Buffer (Life Technologies Italia). 
Numerical data collected during electrophoresis were analyzed 
by GeneScan software (version 3.1; Thermo Fisher Scientific, 
Inc.) to produce graphic and numerical results of dimension of 
amplified DNA fragments. The microsatellite markers employed 
in the present study and their locations were taken from the 
Genome Database (http://www.ncbi.nlm.nih.gov/genome). The 
primers for the MBP gene repeats also amplified two short 
tandem repeat loci (locus A and locus B) (10). Microsatellite 
sequences observed to be most frequently altered in previous 
studies (6,11,12) were selected for the present study. LOH was 
characterised as the complete or almost complete absence of 
one allele in tumour DNA. All molecular tests were performed 
in duplicate using isolated PCR reactions. All available haema-
toxylin and eosin-stained slides of bladder carcinomas were 
reviewed by one pathologist. Specimens were pathologically 
staged according to the 2010 Tumour-Node-Metastasis clas-
sification of the American Joint Committee on Cancer (13) and 
tumour grade was assigned in line with the 2004 World Health 
Organization/International Society of Urologic Pathology clas-
sification (14).
Patients. Following the diagnosis of MIBC, all patients 
underwent radical cystectomy with standard bilateral pelvic 
lymphadenectomy and urinary diversion. Radical cystectomy 
was performed by an expert uro-oncology consultant according 
to the procedure described by the International Consultation 
on Bladder Cancer (15). The lymph node dissection performed 
involved the excision of all lymphatic tissues surrounding 
the common iliac, external iliac, internal iliac and obturator 
arteries as well as the presacral region. Following cystectomy 
and urinary diversion, all patients underwent follow-up exami-
nations, which were performed according to the European 
Association of Urology guidelines (16). In brief, chest x-rays 
and abdominal ultrasound were required every 3 months, 
computerised tomography of the abdomen every 6 months and 
bone scan and excretory urography every 12 months. Additional 
examinations were required for symptomatic disease (16). 
Concomitant urethrectomy was performed only in patients who 
had preoperative histologically proven UC of the prostate and/or 
urethra in association with MIBC (16).
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Statistical analysis. As the null hypothesis, LOH on Chr 18 
was assumed to have no impact on survival rate in patients 
with MIBC. The significance of all parameters was assessed 
using the Fisher's exact test and chi-square test, where P<0.05 
was considered to indicate a significant difference between 
values. The 95% confidence intervals (CIs) were calculated 
for the probability of survival for the Kaplan-Meier estimates. 
Mann-Whitney tests were also used in order to compare the 
means of the different parameters. Univariate and multi-
variate relative risk was calculated using Cox proportional 
hazards regression analysis. SPSS 11.5 for Apple-Macintosh 
(SPSS, Inc., Chicago, IL, USA) was used to perform all 
statistical analyses. 
Artificial Neural Network (ANN) analysis was employed 
in order to enhance the standard statistical analysis, as previ-
ously described (17,18). In brief, a neural network was used in 
order to predict the outcome of patients with MIBC, according 
to the findings of the univariate and multivariate analyses. The 
following factors were the input parameters (input neuron) 
for ANN analysis: Age, gender, number of lesions, diameter 
of lesions, LOH on Chr 18, stage and grade. ANN setup was 
performed using the commercially available NeuralWorks 
Predict software (2005; NeuralWare Inc., Carnegie, PA, USA).
Results
Patient and tumour characteristics. A total of 34 patients 
were enrolled in the present study, 32 of which were male and 
2 were female (mean age, 69.9±8.7). The patient and tumour 
characteristics are detailed in Table I.
Molecular results. At the baseline, 18 (52.9%) patients 
exhibited ≥1 alteration in one of the loci analysed on Chr 18, 
while 16 (47.1%) showed no alterations on Chr 18. Out of the 
Figure 1. Kaplan-Meier curves illustrating the association between LOH 
on chr 18 (HR, 3.45; 95% CI, 2.20-5.10; P<0.001) and cancer-specific sur-
vival patient probability. Mortality was used as endpoint in Kaplan-Meier 
analysis. Time (months), time from initial diagnosis to first recurrence 
(months); LOH, loss of heterozygosis; chr, chromosome; HR, hazard ratio; 
CI, confidence interval.
Table I. Summary of clinical and histopathological patient 
data.
A, Patient characteristics
Characteristic n (%)
No. of patients 34
Mean age ± standard deviation 69.9±8.7
Gender
  Male 32 (94.1)
  Female 2 (5.9)
B, Patient anamnestic, pathological and clinical data
Characteristic n (%)
No. of recurrences/year
  1 16 (47.1)
  2 9 (26.5)
  ≥3 9 (26.5)
No. of lesions
  1 21 (61.8)
  2 7 (20.6)
  ≥3 6 (17.6)
Diameter of lesion (if multiple, 
diameter of the largest)
  <3 cm 24 (70.6)
  ≥3 cm 10 (29.4)
Stage
  pT2 19 (55.9)
  pT3a 7 (20.6)
  pT3b 5 (14.7)
  pT4 3 (8.8)
Grade
  G3 34 (100)
Lymph node involvement 
  N0 28 (82.3)
  N1 6 (17.7)
  N2 0 (0.0)
  N3 0 (0.0)
Previous intravesical therapy 34 (100)
Cigarette smokers 18 (52.9)
Charlson comorbidities index
  <2 26 (76.5)
  2 6 (17.6)
  ≥3 2 (5.9)
Urinary diversion
  Cutaneous ureterostomy 11 (32.4)
  Ileal conduit 6 (17.6)
  Neobladder 17 (50.0)
Mean no. of lymph nodes removed (range) 15.1 (11-23)
Adjuvant chemotherapy 3 (8.8)
pT, primary tumour stage; G, grade; N, node involvement.
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18 patients with altered loci, the MBP LW locus was altered 
in 6 (33.3%), MBP H in 7 (38.9%) and D18S51 in 5 (27.8%) 
patients. In 2 patients the D18S51 locus was singularly 
altered, in 1 patient alterations occurred on both MBP H and 
D18S51 loci and 2 patients exhibited altered MBP LW and 
D18S51 loci.
Follow‑up results. At a mean follow-up duration of 128.6 months 
post-surgery, 11 patients (32.3%) were alive with no evidence of 
disease (mean disease-free survival time, 126.6 months; 95% CI, 
119.2-129.1 months). In addition, 8 patients were alive with 
evidence of tumour recurrence (mean disease-free survival 
time, 10.8 months; 95% CI, 103.5-115.1 months) and a further 
11 patients succumbed to their disease (mean disease-free 
survival time, 23.2 months; 95% CI, 19.7-29.1 months) as well 
as four mortalities from non-associated causes. Cumulative 
cancer-specific survival rates of the whole study group at 1, 3 
and 5 years were 88.2, 64.7 and 52.9%, respectively. No corre-
lation was identified between clinical or pathological factors 
and the detection of LOH on Chr 18. Kaplan-Meier analysis 
revealed a significant correlation between patient status 
at follow-up and LOH on Chr 18 [hazard ratio (HR), 3.45; 
95% CI, 2.20-5.10; P<0.001] (Fig. 1). The comparison 
of microsatellite analysis with follow-up data identified 
significant correlations between altered D18S51 (P<0.001) 
or MBP H (HR, 2.61; 95% CI, 1.80-3.12; P<0.001) loci and 
patient status at follow-up. However, no significant correla-
tion was demonstrated between MBP LW and status at 
follow-up (P=0.6).
Univariate analysis, multivariate analysis and artificial 
ANN results. As determined using univariate analysis, stage, 
lymph node status, LOH on Chr 18 and age proved to be 
significantly associated with patient survival. According to 
the multivariate analysis, the detection of LOH on Chr 18 
(HR, 4.08; 95% CI, 2.09-6.61; P=0.001) and stage (≥pT2; 
HR, 2.23; 95% CI, 1.17-3.46; P=0.01) were identified as inde-
pendent prognostic factors in predicting status at follow-up. 
ANN analysis identified LOH on Chr 18 and stage as the 
most powerful variables affecting the output decision and 
predicting the natural history of MIBC; these results were 
consistent with those obtained by multivariate analysis.
Discussion
Optimal control and management of patients with bladder 
cancer is primarily dependent on appropriate risk-group 
stratification, which is established according to the correct 
assessment of biological and clinical characteristics (19). 
Numerous previous studies have identified several sequential 
genetic events, which were found to be associated with tumour 
natural history (8). A novel bladder cancer susceptibility 
locus, the urea transporter gene SLC14A1 was identified on 
Chr 18q (20,21). In addition, LOH on Chr 18q and 9q was 
reported to be able to predict the clinical outcome of patients 
with bladder cancer (8).
The present study demonstrated that LOH on Chr 18 was 
an independent prognostic indicator of survival in MIBC 
patients. Three loci were evaluated on the q arm of Chr 18 
(18q21-23), where two tumour-suppressor genes, DCC 
(18q21.3) and DPC4 (18q21.1), are located (8). Uchida et al (8) 
suggested that Chr 18q was crucial in the development of the 
malignant phenotype, particularly in bladder cancer (7,8). Of 
note, in the present study, a strong correlation was observed 
between altered D18S51 or MBP H loci and patient outcome. A 
previous study, which investigated non-muscle-invasive UC, 
reported no notable correlation between D18S51 locus and 
status at follow-up (4), emphasising that LOH on Chr 18q22 
(D18S51 locus) may be a late event in bladder tumorigen-
esis (22). Brewster et al (22) demonstrated that loss of genetic 
material on 18q21.3, which includes DCC, was associated 
with MIBC disease and was frequently present in tumour 
recurrences. The results of the present study confirmed that 
alterations in MBP LW and MBP H loci occurred in the 
early phase of bladder tumorigenesis, while the D18S51 locus 
was implicated in a later phase. Therefore, alteration in the 
D18S51 locus identified on tissue samples following TURBT 
may be considered as a negative prognostic factor affecting 
survival in patients with MIBC. A limitation of the present 
study is the small number of the patients analysed, this was 
due to the time-consuming and labour-intensive, thus expen-
sive, molecular biology techniques employed. To the best of 
our knowledge, the current study was the first to demonstrate 
the use of LOH on Chr 18q21-23 in predicting the clinical 
outcome of patients with MIBC; however, further studies are 
required in order to confirm the present findings.
In conclusion, the present study highlighted the role of 
LOH on Chr 18q21-23 in predicting the clinical outcome of 
patients with MIBC. In addition, the present study elucidated 
the feasibility and utility of Chr 18 LOH as a potential 
clinical marker, in conjunction with well-established clin-
ico-pathological factors, for the development of an effective 
adjuvant treatment schedule in MIBC patients.
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